Key result
Captopril reduces hepatic TNF-α and increases IL-10 in bile duct ligated rats.
Why the study?
The renin-angiotensin system plays an important role in hepatic inflammation and fibrosis, and ACE inhibitors like captopril may provide protective effects against hepatic fibrogenesis.
Does captopril improve hepatic cytokine production (TNF-α and IL-10) in bile duct ligated rats?
Does captopril improve hepatic cytokine production (TNF-α and IL-10) in bile duct ligated rats?
In a rat model of bile duct ligation, captopril modulates hepatic cytokine production by decreasing TNF-α and increasing IL-10, suggesting a mechanism for its protective effect against hepatic fibrosis.
Hypothesis-generating for captopril in experimental hepatic fibrosis; leaves open translation to human disease.
BACKGROUND: The renin-angiotensin system has an important role in hepatic inflammation and fibrosis. Renin-angiotensin system blockade by angiotensin-converting enzyme (ACE) inhibitors provides some protective effects against hepatic fibrogenesis. Captopril as an ACE inhibitor can decrease inflammatory mediators and attenuate hepatic fibrosis in the livers of bile duct ligated (BDL) rats. OBJECTIVE: The present study was conducted to investigate the effects of captopril on cytokine production in hepatic fibrosis induced by a bile duct ligation model in rats. METHODS: Male rats were divided into four groups including; control, sham operated, BDL, and BDL plus captopril (10 mg/kg/day, orally). After 28 days of treatment, the livers were removed for cytokine analysis. Hepatic interleukin (IL)-10 and tumor necrosis factor (TNF)-α levels were measured. RESULTS: Captopril treatment decreased the hepatic content of the proinflammatory cytokine TNF-α and increased the anti-inflammatory cytokine IL-10. CONCLUSION: the present study suggests that the protective effect of captopril on hepatic fibrosis is likely to be mediated by cytokine production.
No takes yet. Share an insight, caveat, or question.
Amirshahrokhi et al. (2010) studied Hepatic fibrosis induced by bile duct ligation. Captopril vs. Control, sham operated, and BDL without captopril was evaluated on Hepatic IL-10 and TNF-α levels. Captopril treatment decreased the hepatic content of the proinflammatory cytokine TNF-α and increased the anti-inflammatory cytokine IL-10 in bile duct ligated rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: